Early detection of ovarian cancer, which primarily affects postmenopausal women, could save up to 50,000 lives a year. Complimentary markers to CA125 are clearly needed to effectively monitor all ovarian cancer patients and to provide a panel of markers to diagnose early stage disease.

To date, Stage I has produced serum-based diagnostic tests for five new markers. These five markers, coupled with CA-125, comprise an initial diagnostic panel that has been verified for efficacy utilizing a limited set of serum samples.